Improving IVF Outcomes by Better Embryo Selection with Simon Fishel | Illumina Video

5 November 2014

In IVF, embryos with chromosomal problems cause up to 80% of failures and miscarriage. Preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD) enables us to select embryos free of chromosomal problems for transfer. Illumina advanced reproductive health solutions [link to: http://www.illumina.com/clinical/reproductive-genetic-health.ilmn], such as VeriseqTM and 24sure, empower us to select and transfer embryos that give us the best chance of a successful pregnancy. Empowering informed choices to change lives.

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.